Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Fig. 1

Patient disposition

Note: Some patients may have discontinued the study treatment but remained in the study and completed the 6- or 12-month follow-up for baseline and safety assessments. Premature discontinuation refers to patients who discontinued the study before the specified timepoint

AE adverse event, DAS28(CRP) disease activity score in 28 joints using C-reactive protein, D/C discontinuation, FAS full analysis set, f/u follow-up, LOE lack of efficacy, mFAS modified FAS

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us